Uğur Şahin and Özlem Türeci, the pioneering founders of BioNTech, are set to depart from the company that gained international acclaim during the COVID-19 pandemic. Their exit will occur no later than the end of 2026, coinciding with the conclusion of their current service contracts. The couple plans to establish a new biotechnology firm that will concentrate on advancing the next generation of mRNA-based medications, building on the success they achieved with BioNTech's COVID-19 vaccine.

Despite their departure, Şahin and Türeci will retain approximately 15% ownership of BioNTech, with plans to contribute certain rights and mRNA technologies to their new enterprise. This strategic move is designed to facilitate an ongoing relationship between the new company and BioNTech. In return for these contributions, BioNTech will receive a minority stake in the new firm and ongoing license fees, as well as milestone payments tied to the achievement of specific development targets, ensuring that BioNTech continues to benefit from their innovations.

Since founding BioNTech in 2008, Şahin and Türeci have garnered numerous awards and succeeded in generating substantial profits, especially during the height of the pandemic. Their decision to launch a new venture indicates their commitment to leveraging mRNA technology, which has transformed the pharmaceutical landscape, particularly in vaccine development. The implications of this new company could further enhance the role of mRNA in treating various diseases, marking a pivotal moment in biopharmaceutical innovation.